Cochrane · systematic review · CD011616
Botulinum toxins for the prevention of migraine in adults
Herd, CP, Tomlinson, CL, Rick, C, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
12
No studies
1
Included studies
NR
No studies 1 · 7.7%Ungraded 0 · 0%Very low 8 · 61.5%Low 2 · 15.4%Moderate 1 · 7.7%High 1 · 7.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Botulinum toxin type A compared to placebo for the prevention of migraine in adults
Population: adults with migraine
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of migraine days per month: chronic migraine only Botulinum toxin type A vs placebo | no estimate extracted | 4 studies · 1497 participants | Low Downgraded: imprecision, inconsistency |
Number of migraine days per month Botulinum toxin type A vs placebo | no estimate extracted | 5 studies · 1915 participants | Very low Downgraded: imprecision, inconsistency, indirectness |
Number of headache days per month: chronic migraine only Botulinum toxin type A vs placebo | no estimate extracted | 2 studies · 1384 participants | High |
Number of migraine attacks Botulinum toxin type A vs placebo | no estimate extracted | 6 studies · 2004 participants | Low Downgraded: indirectness, publication bias |
Headache intensity measure (Visual Analogue Score 0‐10) Botulinum toxin type A vs placebo | no estimate extracted | 4 studies · 209 participants | Very low Downgraded: risk of bias, imprecision |
Global impression scale Botulinum toxin type A vs placebo | no estimate extracted | 1 study · 45 participants | Very low Downgraded: risk of bias, imprecision |
Total number of participants experiencing an adverse event Botulinum toxin type A vs placebo | RR 1.28 [1.12, 1.47] | 13 studies · 3325 participants | Moderate Downgraded: imprecision |
Botulinum toxin type A compared to other established prophylactic agent for the prevention of migraine in adults
Population: adults with migraine
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of migraine days per month: chronic migraine only Botulinum toxin type A vs other established prophylactic agent | no estimate extracted | 1 study · 43 participants | Very low Downgraded: risk of bias, imprecision |
Number of headache days per month Botulinum toxin type A vs other established prophylactic agent | no estimate extracted | 1 study · 59 participants | Very low Downgraded: risk of bias, imprecision |
Number of migraine attacks per month Botulinum toxin type A vs other established prophylactic agent | no estimate extracted | NR | No studies |
Headache intensity measure Botulinum toxin type A vs other established prophylactic agent | no estimate extracted | 1 study · 46 participants | Very low Downgraded: risk of bias, imprecision |
Global impression of disease Botulinum toxin type A vs other established prophylactic agent | no estimate extracted | 2 studies · 101 participants | Very low Downgraded: risk of bias, imprecision |
Total number of participants experiencing an adverse event Botulinum toxin type A vs other established prophylactic agent | RR 0.76 [0.59, 0.98] | 2 studies · 114 participants | Very low Downgraded: risk of bias, imprecision |